# Lowering Drug Costs: Rethinking PBMs, Pricing and Patient Access with Dr. Ezekiel Emanuel & Miriam Paramore

- **Show:** Becker's Healthcare Podcast
- **Published:** 2 Sep 2026
- **Source:** https://podcast.show/beckershealthcarepodcast/episode/155247672/
- **Transcript:** https://podcasts.opennash.com/shows/beckers-healthcare-podcast/lowering-drug-costs-rethinking-pbms-pricing-and-patient-access-with-dr-ezekiel-e-141770/
- **Provider:** OpenNash Podcasts (machine-generated)

## In brief

Prescription drugs are unaffordable mainly because of administrative layers and opaque pricing rather than production cost. Ezekiel Emanuel and Miriam Paramore argue for splitting the market in two: make generics free at the pharmacy counter, with a few safe old drugs sold over the counter, and use government price regulation for expensive brand-name drugs, where patients cannot realistically shop around.

The tension runs between consumer power and its limits. Paramore shows that direct-to-consumer sales, as with Eliquis and GLP-1 drugs, quickly cut prices when patients can see and pay them. Emanuel counters that no patient can shop for a $10,000-a-month cancer drug, so regulation is needed. Both agree the web of rebates and middlemen adds little value and should be simplified or removed.

## Key insights

1. **Direct-to-consumer sales can sharply cut drug prices** Paramore says Eliquis's patient-paid list price fell from about $600 to $349 once it was sold directly to consumers, and $249 from a Canadian pharmacy. Host Scott Becker notes GLP-1 prices fell by half or more through direct channels.
2. **Generic drugs should carry no copay or deductible** Emanuel notes about 90% of prescriptions are generics that cost pennies per pill to make. He argues copays and deductibles only stop patients taking medicine that would keep them healthy, so removing them should improve adherence and outcomes.
3. **Brand-name drugs need government price regulation** Emanuel says patients have no shopping power over $10,000 to $20,000 monthly drugs. He notes the US lets companies hold patents and then set the price, and he favors an Australian-style system where each new drug class gets one price.
4. **Insured prices are often higher than cash prices** Paramore says a $15 insurance copay can cost $2 in cash, and a pharmacy coupon could bring Dupixent to zero. Patients are rarely told these options exist, so pricing stays opaque.
5. **Uniform class pricing could make PBMs unnecessary** Emanuel says a pharmacy benefit manager (PBM) mainly builds a formulary, a preferred-drug list, to win better prices. If every drug in a class sells at the same price, that function has nothing left to do.

## Questions this episode answers

### Why are prescription drugs so expensive in the US if many cost pennies to make?

Emanuel says administrative add-ons around generic drugs cost far more than producing and selling them. He and Paramore also say many middlemen take a share of the money while adding little or no value.

### What is the difference between a drug's list price and its net price?

Paramore says the list price is a 'made up' number that patients may pay when they haven't met their deductible. Insurers, PBMs and employers pay the lower net price, which for Dupixent she says is about $1,000 against a $2,500 to $4,000 list price.

### What do Emanuel and Paramore propose for cheap generic drugs?

They propose removing copays and deductibles for tier-one generics so patients actually take them. They also want a small set of old, proven-safe drugs, perhaps 30 to 40, sold over the counter.

### Should we get rid of pharmacy benefit managers (PBMs)?

Emanuel says probably yes, if drug pricing is changed so all drugs in a class cost the same, because a PBM's main job is negotiating a preferred-drug list. He says a distributor function would still be needed.

### Can shopping around bring down the cost of cancer drugs?

Becker and Emanuel say no. Patients can't realistically price-shop for cancer or cardiovascular treatment, so consumer pressure works for generics but expensive brand drugs need regulation.

## Facts

- **Ezekiel Emanuel** [0:02:27]: "Between 2009 and 2011, I was in the White House at the Office of Management and Budget and the National Economic Council, working on the Affordable Care Act"
- **Ezekiel Emanuel** [0:03:05]: "And then I came to the University of Pennsylvania, where I am a professor and a vice provost of global initiatives"
- **Miriam Paramore** [0:00:48]: "I'm the founder and CEO of RxUtility, and I'm not famous."
- **Miriam Paramore** [0:08:10]: "My sister was diagnosed with breast cancer two years ago, had a double mastectomy."
- **Miriam Paramore** [0:08:47]: "And they said, Cigna has denied your anesthesiologist."
- **Miriam Paramore** [0:13:27]: "we have more price points for the same drug than we've ever had before."
- **Miriam Paramore** [0:13:56]: "the payers, the PBMs and the employers, they all pay off of net."
- **Miriam Paramore** [0:15:03]: "GoodRx made a great shift in our industry when they said, we think people should know what drugs cost"
- **Miriam Paramore** [0:16:07]: "And the other thing is they're saying we should include the Trump Rx prices in the real-time pharmacy benefit check return."
- **Scott Becker** [0:17:34]: "31 million people are on GLP-1s. A huge percentage of those are getting them now, not through payers"
- **Scott Becker** [0:18:25]: "Cigna recently, I think it was Cigna or Aetna recently said they're no longer covering for their employees"
- **Miriam Paramore** [0:19:39]: "list price that patients are paying out of their own pocket when they're in their deductible phase for Eliquis was $600."
- **Miriam Paramore** [0:20:10]: "$349. And do you know if you get it from a Canadian pharmacy, it's $249."
- **Scott Becker** [0:12:52]: "you've seen Civica coming out of Intermountain try and provide an ability or a bunch of nonprofits, but trying to provide a generics alternative"
- **Ezekiel Emanuel** [0:22:41]: "whatever, 90 % of prescriptions are generic drugs."
- **Ezekiel Emanuel** [0:23:50]: "We know they're safe. We've been using them for 60, 70 years. They're safer than Tylenol and Aspen."
- **Ezekiel Emanuel** [0:24:22]: "we're one of the only countries that gives drug companies patents and then says, set the price."
- **Ezekiel Emanuel** [0:24:59]: "My own favorite idea, it really comes out of Australia, I mean, which is you get a price for a new class of drugs."
- **Ezekiel Emanuel** [0:26:53]: "What's the main focus of a PBM? Putting together a formulary to get the better pricing for the sponsor."
- **Miriam Paramore** [0:29:05]: "We are hoping to be the Expedia for drug prices, Scott."
- **Scott Becker** [0:05:08]: "27 ,000 oncologists in the country practicing or somewhere around there, 27 to 28 ,000."

## Transcript

**[0:00:00] Scott Becker:** This is Scott Becker with the Becker's Healthcare Podcast. I'm thrilled today to visit with two brilliant leaders in healthcare. We're dealing today with Dr. Ezekiel Emanuel and Miriam Paramore. We're going to talk today about affordability of pharmaceuticals, affordability of drugs, which is a huge problem in our country. It has been for as long as I can remember. Getting worse in some spots with niche and specialty drugs, getting better in some places with generics and some other opportunities where people are going to market.

**[0:00:30] Scott Becker:** But Dr. Emanuel, of course, is famous. And Miriam Paramore is brilliant. So we've got famous and brilliant with us. Looking forward to visiting with the both of you. Miriam, can I ask you to take a moment to introduce yourself? And then Dr. Emanuel, I'll ask you to do the same.

**[0:00:48] Miriam Paramore:** Thank you, Scott. It is really a pleasure for me to be here. I've known you from afar for my whole career. So really appreciate the chance to talk with you. I'm Miriam Paramore. I'm the founder and CEO of RxUtility, and I'm not famous. But in healthcare, I am known because I've been in healthcare for so long, always on the healthcare technology and health IT side. And the business of RxUtility is focused on helping people save money on medicine.

**[0:01:17] Miriam Paramore:** So it's a kind of a very mission-driven business. And I had the good fortune to recently meet Zeke. and I said, I've read your book, his ice cream book, which I love. And he sort of put me on the spot, like he was asking me questions that I'm testing. Remember, Zeke, you were testing me had I read it, and I had read it. So I said, yeah, I have these questions. And then it evolved into a quick conversation.

**[0:01:43] Miriam Paramore:** Well, what are two things you would do to lower the cost of meds if you could do anything right now? And Scott, the two things we talked about in our op-ed just came out of my mouth, and then Zeke was interested and we built on it. And so, you know, just happy and thrilled to be here.

**[0:01:59] Scott Becker:** Fantastic. And I want to dig into this closely. There's so much activity going on and people trying to find ways to make drugs more affordable. And I'd love to hear what you're doing and what it looks like. Dr. Emanuel, can you take a moment, tell people about sort of your background. You worked in the White House at one point, I believe, or with the federal government, have been crafting healthcare policy for a long time, brilliant leader and thinker.

**[0:02:25] Scott Becker:** Tell us about your background, both as a physician

**[0:02:27] Ezekiel Emanuel:** and as a healthcare policy person. So I'm an oncologist. And for the first, I would say, 20 years of my life, known as a bioethicist, working on things like end-of-life care, research ethics, and allocating resources. Between 2009 and 2011, I was in the White House at the Office of Management and Budget and the National Economic Council, working on the Affordable Care Act and a variety of other things like the food plate and global health supports such as PEPFAR.

**[0:03:05] Ezekiel Emanuel:** And then I came to the University of Pennsylvania, where I am a professor and a vice provost of global initiatives and continue to work on mainly health policy, as well as some bioethical issues around allocating things like the COVID vaccine. That was something I spent a lot of time on. And for the last few years, I've really been focused on, we've got to dramatically reform, disrupt, whatever phrase you want to use, our healthcare system, and how to think about that to get universal coverage, reasonable and sustainable costs, and consistent high quality and diminishing disparities.

**[0:03:50] Ezekiel Emanuel:** And obviously, a major focus of the affordability and cost problem are drugs. And I was lucky enough to meet Miriam, who has a number of brilliant ideas. And we crafted, I think, a simple cost-saving measure that is good for patients, good for the country. You don't come across those every single day.

**[0:04:14] Scott Becker:** Thank you. I'm going to ask you three very quick follow-up questions, and I'm going to turn to Miriam and how we're going to try and save money on drug costs. But, Dr. Emanuel, the first concept is, do you work with Kevin Mahoney at all at University of Pennsylvania? Do you get to visit with Kevin?

**[0:04:32] Ezekiel Emanuel:** All the time. Actually, I think Kevin and I are having a dinner with some people in 10 days.

**[0:04:41] Scott Becker:** He is an unusually thoughtful and gifted leader, as you know. He's got this incredible ability to be a leader and make sure that he doesn't feel like a top-down leader, just a tremendous vision on how to build and work with people. And what he's done at the University of Pennsylvania or Penn Medicine is truly remarkable. The second question is on oncology one. And this goes to the heart of so many things we talk about and think about.

**[0:05:08] Scott Becker:** 27 ,000 oncologists in the country practicing or somewhere around there, 27 to 28 ,000. 2 million new diagnoses of cancer a year. Every oncologist that we work with or see is exhausted, burnt out, and is information overload. Is there a solution to that? Are there solutions to this? And we'll come back to drug pricing in a second because it's such an important thing. But is there a – and the same with universal coverage. Most of us in healthcare are huge fans of universal coverage.

**[0:05:41] Scott Becker:** We want coverage for all. But I'm a believer that coverage for all without fixing the supply problem is somewhat of an illusory discussion, somewhat of a political platitude discussion by many people. Coverage for all. I want coverage for all. But I recognize coverage for all without fixing supply is almost garbage. It's almost a talking point, but you need both. You need to fix supply and be able to take care of people. What I would think about more is health care for all versus coverage for all, and they're very different things.

**[0:06:08] Scott Becker:** So how do you think about this cancer oncologist shortage and think about coverage for all versus health care for all?

**[0:06:14] Ezekiel Emanuel:** Well, I'm not sure it's so much of a shortage as you have a situation where oncologists are peppered with a lot of administrative hassles and the support structures are diminishing. You know, almost every patient has multiple prior authorizations. They take a lot of time. They take a lot of distraction. They delay care. You've got a lot of oncologists having to deal with drug shortages of chemotherapy agents. And I think all of this combines to create an environment where doctors are distracted rather than primarily focused on delivering good patient care.

**[0:06:59] Ezekiel Emanuel:** I do think this is a case, Scott, and this is a whole other topic where AI could help a lot. Having AI manage patients' side effects from chemotherapy is probably something that's, I say easily, but very doable in the next few years. And I think that could really reduce the workload of doctors and the pressures on them, solving the prior authorization problem. So if a doctor's providing guideline concordant care, there's no prior authorization related to it.

**[0:07:37] Ezekiel Emanuel:** I think those are the kinds of changes that we really do need to see in healthcare to make it more workable for physicians. I think that's well, well stated.

**[0:07:49] Scott Becker:** I do think there's a lot more to it than that, but I do think those are very important parts. I mean, with AI right now, I talked to oncologists who are having 50 of their patients summarize for them very quickly. And now the oncologist is overwhelmed trying to figure out what to do with those 50 patients. I mean, it's really a fascinating challenge. And AI is very, very important. But I do think it's a little bit of both.

**[0:08:07] Scott Becker:** But, Miriam, let me turn it to you. Sorry about that.

**[0:08:10] Miriam Paramore:** Yeah, no, no, that's fine. I just wanted to jump in and add, from a patient's point of view, my sister was diagnosed with breast cancer two years ago, had a double mastectomy. I spent an hour and then reconstruction and complications with reconstruction and then so many side effects from the drug she's supposed to take to keep certain things suppressed after she was luckily stage one. One, it had was in her lymph nodes a little bit, but it was caught really early, but severe side effects.

**[0:08:47] Miriam Paramore:** And watching the fragmentation and going through with it, holding her hand, having her get to the hospital. Literally, this happened at 515 in the morning for her double mastectomy to go to the window to check in. And they said, Cigna has denied your anesthesiologist. And so that's literally she's going in. And so that's prompted me to write, would you like some anesthesia with your surgery, which was a piece I put out on LinkedIn. There's nothing more ridiculous than these sorts of things, Scott.

**[0:09:19] Miriam Paramore:** But the other piece I wanted to say about supply and demand, the amount of work that patients who have a serious illness or lots of illnesses with multiple doctors, the fragmentation around just one quote episode or treatment journey like my sister had, which had a good outcome. There is insufficient communication with patients about how all these things interact. You have supposedly a primary care doctor. Then you have like this lymphoma people. You've got the surgeon who says something other than the oncologist.

**[0:09:55] Miriam Paramore:** You have reconstruction people who don't talk to these other people. You have side effects management after the fact. And what my sister and her good friend, who I spent two hours with this weekend talking about, my sister's much more severe. It's the hers triple negative, not the triple positive, but the triple negative, something like that. So she is a much longer or much more difficult situation. Scott, they are both using chat to try to get answers they cannot get from the health care system.

**[0:10:29] Miriam Paramore:** They cannot get the answers from the doctors. The doctors don't talk to each other. And they recently found that both these women, who I love, this supplement interaction and that supplements that they were supposed to be taking, they shouldn't be taking in certain cases because of the drug regimen they're on. The amount of time that was brought up to either of them by anybody, zero.

**[0:10:56] Scott Becker:** No, but I think what happens is I think so much what you're saying is completely correct. I could not agree more. Or the anesthesia before surgery is saying, oh, that's an add-on is crazy, of course. That just is insane. But this concept of the doctors don't talk to each other, the teams don't talk to each people working in silos is one of the reasons why 50 years after my grandma used to go to Mayo Clinic, people are still going to Mayo Clinic, still going to Cleveland Clinic because they've still got the whole team approach.

**[0:11:24] Scott Becker:** And of course, a lot of staff, of course, a lot of people to go with a lot of artificial intelligence and a lot of technology. And just like the experience of your sister and her friend, all of us are going to CH-EPT whenever we've got a symptom today as a starting point. But what happens is it's not reducing the need for doctors because you still need doctors and nurse practitioners and PAs on the back end to actually deal with people.

**[0:11:52] Scott Becker:** It's sort of trust plus verify. We need great technology and AI systems know they're underinvested in care navigation. I think systems as a whole, you'll talk to the greatest systems in the city here in Chicago, and they'll tell you very clearly, we've underinvested in care coordination, care navigation, partly because we don't get paid for it, even though we know what you're real need. So like when you get through your very complex surgery, you end up going to one of the more local institutions for your follow-up on radiation therapy, just because the care coordination at the greatest academic medical Center is still a challenge and a real challenge.

**[0:12:26] Scott Becker:** So I think I agree with everything you're saying, but the only thing I would say is that I do believe that we are, regardless of all the things that go right with technology and as they evolve and so forth, we're still going to need, I'm a trust but verify person. I'd like to have more oncologists. All of us are in age where we've seen so many people die from cancers. We found the bench was much shorter than we thought it was, in terms of oncology.

**[0:12:52] Scott Becker:** But Mary, let me turn to drugs and what you see there and where you folks are facing and what you're trying to accomplish there. I mean, obviously, you've had people like Mark Cuban with Cost Plus try and blow this up a little bit. You've seen Civica coming out of Intermountain try and provide an ability or a bunch of nonprofits, but trying to provide a generics alternative for just generics that couldn't be fine. Some people end up back with with higher cost, non-generic drugs.

**[0:13:21] Scott Becker:** What is the approach of RxUtility, and how are you guys approaching this, and what do you see out there?

**[0:13:27] Miriam Paramore:** So we've got two different things, and when we go back to Zeke, we'll talk about the policy recommendations for a minute. But to talk about sort of medication affordability and price transparency, there really is no price transparency around medication until the individual healthcare consumer steps up to the pharmacy counter and is told what they owe. Okay. And that is happening at exactly the same time, Scott, that we have more price points for the same drug than we've ever had before.

**[0:13:56] Miriam Paramore:** So we have a whole new channel of pricing that used to exist until last year called direct to consumer or direct to patient manufacturer pricing. We have people who pay on the made up number called list price, which is a completely fake number when they get to the pharmacy counter if they haven't met their $10 ,000 deductible like me. OK, but guess what? But the payers, the PBMs and the employers, they all pay off of net.

**[0:14:27] Miriam Paramore:** So that's a good example of something that's a positive outcome out of PBM reform. right but but it has to be selected the self-insured employee the plan sponsor still has to opt in to this idea of true rebate pass through to the point of sale and of course we've got the enforcement issue so in addition to that we've got the rise of the use of cash because we've already paid premiums but then we find out that we're paying a $15 out-of-pocket copay when it would cost you $2 if you paid cash, right?

**[0:15:03] Miriam Paramore:** So we've got the rise in the price of cash. Mark Cuban's made a lot of noise. GoodRx made a great shift in our industry when they said, we think people should know what drugs cost a thousand years ago. It's really been 12 years since they started that business. But cash is not a price. Cash is a category of prices, right? There's the direct to patient price. There's the cash discount card price, which Mark Cuban has his own cash discount, you know, et cetera.

**[0:15:33] Miriam Paramore:** So you can find at any point in time, your insured price is more expensive than your cash. But if you use a pharmacopay coupon, oh, what's that? We don't tell people those exist. You could actually pay zero for a drug like Dupixent that would otherwise list for between 25 and 4 ,000, $2 ,500, $4 ,000 a month, except the net is really only $1 ,000. But you don't know that as a consumer. So there is complete opacity.

**[0:16:07] Miriam Paramore:** And one of the great things that this PBM reform policy does is, again, patients must be able to pay on net if there is something that's a net. And the other thing is they're saying we should include the Trump Rx prices in the real-time pharmacy benefit check return. But what we really should do, Scott, is include the prices. TrumpRx doesn't have all the drugs and TrumpRx isn't always the cheapest. And consumers, I believe, plan sponsors have a fiduciary responsibility to human being, individual people like you and me and Zeke, to have a fiduciary responsibility to us about how much is this going to cost me for this drug?

**[0:16:57] Miriam Paramore:** And we have all the data and technology. We just don't make it available to consumers. And it's been an intentional choice by the industry.

**[0:17:09] Scott Becker:** no question no question and and and i'd love to in a moment i want to ask you another question as a follow-up question on on drug pricing and drug categories is what i find so fascinating is this glp1 evolution and and and because it's it's it's potentially a model for other drugs as well obviously not drugs you need for different conditions or when you're in the hospital but the The GLP-1 thing to me is fascinating.

**[0:17:34] Scott Becker:** 31 million people are on GLP-1s. A huge percentage of those are getting them now, not through payers, but a lot cheaper through direct consumer efforts, whether the hims and hers, the rose sparks, all kinds of other ways. And there's so much that's right about that in that, and there's so much that's challenging about it. But you've almost got almost one click prescribing. You don't know if really a doctor's reviewing it or not. You really don't know.

**[0:18:01] Scott Becker:** I don't mean that in a bad way or a good way. You just don't really know because, you know, it goes into a black box and somebody responds. It's OK. But 31 million people are getting them. And not too long ago, it was a thousand bucks a month. And they were all going through hospitals and health systems and primary care practices and other practices and overwhelming those practices and systems that were already overwhelmed. Now it's being done a completely different way.

**[0:18:25] Scott Becker:** The cost is cut in half, if not by more. And it seems like by two thirds in a lot of places. And if you're getting that, if you're, you know, if you have the risk tolerance to do the compounded ones even more, but that's 90 % cheap for the compounded ones. They are. And you see Cigna recently, I think it was Cigna or Aetna recently said they're no longer covering for their employees because they're basically saying we give up.

**[0:18:50] Scott Becker:** It's cheaper for you to go that way. Just do it that way. And it doesn't work from an insurance standpoint when the insurance company is getting charged $1 ,000 a month and premiums are $1 ,000. They just don't work. The numbers don't work. But it is amazing to me how quickly this corrected itself. It's not perfect, but how much it fixed itself. I don't know if it fixed itself, but how it improved, took the burden off the health systems, took the burdens off the primary practices, cut the cost dramatically.

**[0:19:14] Scott Becker:** You mentioned, right, two-thirds to 90 % if you're willing to do the compounded, you know, which to me still depends what day it is, whether I'm scared of that or not versus a name brand. But the name brands got cut in half. The semi-compounds got cut by 90%. Absolutely, the compounded. But it's fascinating to see that evolution. Is there anything there that's useful for other stuff, or is that just one big category so it doesn't necessarily translate to some other pieces?

**[0:19:39] Miriam Paramore:** It is useful for other stuff, and I want to give this back to Zeke in a moment. But Eliquis, one of the number one drugs in the world, is now sold direct to the consumer. Do you know what happened to the price of Eliquis? Almost cut in half. list price that patients are paying out of their own pocket when they're in their deductible phase for Eliquis was $600. It's Mark Cuban's favorite example. Do you know what the list price of Eliquis is now?

**[0:20:10] Miriam Paramore:** $349. And do you know if you get it from a Canadian pharmacy, it's $249. But what happened, Scott, when we went direct to consumer, but it just shows the power of consumerism in a real market. If consumers want it, they're going to get it. And the manufacturer slash supply chain is going to respond. I thought it was wonderful when Eloquist got on that list. My prediction, more and more and more of that will happen. It creates an opportunity for us in the healthcare system at large.

**[0:20:45] Miriam Paramore:** And Zeke, you told me what you think, but this is very analogous to our recommendation of just make the tier one generics free because of all of the benefit that it has on adherence and better outcomes, and then put these drugs that are OTC and every other similar country, Scott, that have been around for decades and they're safe, make them OTC because all we're doing is inflating the administrative costs, depressing access, and hurting people on affordability basis, like Zeke's patient that was in our article.

**[0:21:23] Miriam Paramore:** Those are simple things that short

**[0:21:25] Scott Becker:** of total reform, you know. But they're just huge wins. They're huge wins that are out there to be had. And your point on when a consumer is paying it for it directly, there's this old adage in business. And obviously, Zeke has got these brothers that are heavily into the business world or have been. It's that when you're doing business with other people's money, If somebody else is paying for it, you're not nearly as true a consumer.

**[0:21:51] Scott Becker:** So it's the old – I'm a lawyer by background. The last thing we want is an individual client. We want clients that are from big companies where it's not coming out of their pocket when they pay the bills. Not good or bad, but any business. You want to be in the other people's money business because people don't watch the cost. So clearly, if we get drugs to be where people are paying for them directly, the costs go down because people won't tolerate the $1 ,000 a month.

**[0:22:14] Scott Becker:** They won't tolerate the $600 a month. And just like we're periodically, we were at an event, a conference in Mexico, and it's amazing the amount of stuff you could buy for almost nothing that is the same stuff that we have here that cost a fortune here. I mean, it's literally, it's ludicrous. It's all locked up and going through payers, going through PPMs, going in other ways. Zeke, let me turn it to you. What are some of the answers here?

**[0:22:40] Scott Becker:** What can we do?

**[0:22:41] Ezekiel Emanuel:** Well, look, we have to recognize that whatever, 90 % of prescriptions are generic drugs. And as Miriam has made clear, we've added all sorts of administrative add-ons to drugs that to produce are pennies per pill. And the administrative costs are way in excess of the production and supply and sales costs. And we need to, I believe, look, I'm an oncologist, right? What we want is our patients to take the medication. When a doctor prescribes a pill, we want them to take the medication.

**[0:23:21] Ezekiel Emanuel:** What does a deductible and copay do or a high drug price do? It impedes patients taking medications that are going to make them healthy. And that is not the place we need to be in our healthcare system. So our proposal, get rid of the copay and deductible on generic drugs, seems to be very straightforward. As Miriam says, there are a whole handful of drugs, 30, 40, you can, you know, depends on, as you pointed out, your risk tolerance, that are safe.

**[0:23:50] Ezekiel Emanuel:** We know they're safe. We've been using them for 60, 70 years. They're safer than Tylenol and Aspen. Let's just put it that way. And we should have them over the counter. That doesn't get to the brand name drugs that are $10 ,000, $20 ,000 a month. And for those drugs, we're going to need federal government drug price regulation. No patient is going to have the shopping power to actually change those pricing. So we need to deal with these two different segments of the market differently.

**[0:24:22] Ezekiel Emanuel:** One, the generics, I think we can get patients to actually change the market, and the prices should be low by getting rid of those copay and deductibles. The other, I think the brand names, we're one of the only countries that gives drug companies patents and then says, set the price. And we know, basic economics tells you what happens. We need drug price regulation there. And we also need, as Miriam has eloquently pointed out, we need to clean up the whole mess.

**[0:24:59] Ezekiel Emanuel:** Everyone's taking a piece of this pie and adding not much value or even no value. And that has to stop. The rebates and all of the other elements, we just need to have uniform pricing. My own favorite idea, it really comes out of Australia, I mean, which is you get a price for a new class of drugs. Every new drug that comes on gets that same price unless it's got some big advantage like fewer side effects or more efficacy.

**[0:25:32] Ezekiel Emanuel:** And the price drops. Once you have a me too drug, the price should drop and the price should drop again. And we need to have some system like that so that we don't have, as Miriam nicely points out, hundreds of prices for the same damn drug.

**[0:25:49] Scott Becker:** One of the things that I love that you said was this differentiation between the generics or the lower-priced drugs and the high-priced specific therapeutic drugs that are brand new and so forth. You know, people talk a lot about, you know, shopping for care, but we know that for lots of regular stuff, people will shop for care and price shop, but you're not shopping for care, at least price-wise, on cancer, on cardiovascular disease, on other things.

**[0:26:18] Scott Becker:** And I think this concept that somehow or another patients could be in the loop on shopping for care for expensive drugs or that if price transparency would somehow or another fix our situation on, you know, cancer or, you know, cardiovascular or any high sort of cost serious thing is just is sort of challenging and misguided. That that consumerism is not going to fix that. We need to find a way to ensure that and do it the right way.

**[0:26:46] Scott Becker:** But let me ask you, should PBMs be out of the game? Should there be no PBMs? Do they not fill a need anymore?

**[0:26:53] Ezekiel Emanuel:** I don't think they do. And if you change the pricing system, okay, so that all the drugs in a class have the same price, I don't think you would need a PBM. What's the main focus of a PBM? Putting together a formulary to get the better pricing for the sponsor. But if you don't need a formula, because all the drugs in that class are at the same price, seems to me, you know, you've gotten rid of the formula.

**[0:27:19] Ezekiel Emanuel:** You don't really need the PBM function. You do need a distributor function, but that's a whole different story.

**[0:27:25] Scott Becker:** I know we're going to run out of time in a moment, so I'm going to ask each of you one more question. Zeke, you may get a non-serious question. Miriam, you're going to get a serious question. Okay, just so you're prepared. That's the smart one. his. So here's the, well, yeah, I wouldn't say it like that. Zeke, no no. You're brilliant yourself. Zeke, of the two brothers, Ari and Ram, who is more fun to hang out with?

**[0:27:54] Scott Becker:** Who is more fun to visit with? And who is more argumentative? I've had the chance to argue with Ram and that's not an easy task. I don't know Ari other than from TV and entourage and so forth, but who is the more fun brother to hang out with? Who is more fun to argue with? And then Miriam,

**[0:28:11] Ezekiel Emanuel:** I'm going to ask you a much more serious question. It all depends what you're doing. You want to go fly fishing? You go with Rahm. You want to go and hang out and do surfing or hang out at the beach or talk about the latest health activity? You hang out with Ari. But I will say this, both of them are argumentative, and, you know, when they're dealing with their older brother, both of them are super critical, so I always go to my gatherer brothers wearing armor.

**[0:28:45] Scott Becker:** Sounds like it makes a lot of sense. Oh, my God. I have a great Ram story for another time, but fantastic. Miriam, tell us where we can learn more about your work and what you do. You're fitting a critical need that's got to be solved. It's a debacle right now in our country. How do we, where can we learn more about your work?

**[0:29:05] Miriam Paramore:** Well, you can follow me on LinkedIn, Miriam Paramore, or our company page, rxutility.com. We are hoping to be the Expedia for drug prices, Scott. We want to surface them all and let the prices flow, democratize the prices. So they flow through all these workflows. And then I'm going to continue to work with Zeke on the policy side to see if we can't just get rid of some of the nonsense that we have around

**[0:29:36] Scott Becker:** access and affordability. Well, we are so thankful for the chance to visit with the two of you today. Truly the highlight of my day. I know our listeners will enjoy it tremendously. Thank you, Trent, as well. But what a pleasure to deal with Dr. Manuel and Miriam Paramore. Just fantastic.

**[0:29:52] Miriam Paramore:** Thank you folks so much. Thank you, Scott. Thank you so much. Thank you.
